MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. (Sunovion) announced today that they will be recruiting investigators for their ongoing STEDESA™ (eslicarbazepine acetate [ESL]) clinical studies, as well as presenting clinical study data during the scientific poster sessions at the 2011 annual meeting of the American Academy of Neurology (AAN) in Honolulu, Hawaii. STEDESA™ is the company’s proposed trade name for eslicarbazepine acetate.
